ZBH · 8-K · 20260805PR335108
Product Launch and Transition
ZIMMER BIOMET HOLDINGS, INC. · 2026-08-05 · Importance 41 · Surprise 58 · In source text
New product introductions contributed positively to 2025 volume and mix trends and supported growth in Knees, Hips, and Technology & Data, Bone Cement and Surgical products. S.E.T. growth included 12.5% growth in CMFT, 8.2% in upper extremities, and 5.5% in sports medicine. Zimmer Biomet decided to discontinue certain products by 2032, reducing expected demand for related inventory and undeployed instruments. The company recognized approximately $170 million to reduce those assets to net realizable value.
Key facts
- Zimmer Biomet expects Monogram commercialization to begin in 2027; Monogram IPR&D will be reclassified and amortized upon commercialization. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | — | Zimmer Biomet expects Monogram commercialization to begin in 2027; Monogram IPR&D will be reclassified and amortized upon commercialization. |